Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
10502 studies found for:    NCI
Show Display Options
Rank Status Study
21 Withdrawn Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gallbladder;   Adenocarcinoma With Squamous Metaplasia of the Gallbladder;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Stage II Gallbladder Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: selumetinib;   Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Procedure: quality-of-life assessment
22 Completed Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
23 Recruiting Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Placebo;   Other: Laboratory Biomarker Analysis
24 Completed Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma
Interventions: Biological: rituximab;   Biological: recombinant interleukin-12;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
25 Completed Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: cixutumumab;   Drug: temsirolimus;   Other: pharmacological study;   Other: laboratory biomarker analysis
26 Completed Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Conditions: Childhood Central Nervous System Germ Cell Tumor;   Childhood Extragonadal Germ Cell Tumor;   Childhood Hepatoblastoma;   Childhood Hepatocellular Carcinoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Malignant Ovarian Germ Cell Tumor;   Childhood Malignant Testicular Germ Cell Tumor;   Childhood Teratoma;   Recurrent Adrenocortical Carcinoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Colon Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Nasopharyngeal Cancer;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer
Intervention: Drug: oxaliplatin
27 Completed
Has Results
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
Conditions: Lip and Oral Cavity Cancer;   Oral Leukoplakia;   Oropharyngeal Cancer;   Tongue Cancer
Interventions: Drug: Bowman-Birk inhibitor concentrate;   Other: placebo;   Other: laboratory biomarker analysis
28 Completed Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Aldesleukin;   Biological: gp100 Antigen;   Drug: Montanide ISA 51 VG;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Laboratory Biomarker Analysis
29 Completed Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
30 Completed
Has Results
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: docetaxel;   Drug: bortezomib;   Other: laboratory biomarker analysis;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: pharmacological study
31 Terminated EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
Conditions: Advanced Malignant Mesothelioma;   Localized Malignant Mesothelioma;   Malignant Ascites;   Primary Peritoneal Cavity Cancer;   Recurrent Malignant Mesothelioma
Interventions: Drug: etanidazole;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
32 Completed EF5 in Treating Patients With Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: EF5;   Procedure: therapeutic conventional surgery;   Procedure: biopsy;   Other: pharmacological study
33 Completed FR901228 in Treating Patients With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma (Cancer) of the Head and Neck
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis
34 Completed
Has Results
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: alvocidib;   Drug: docetaxel
35 Terminated 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome
Interventions: Drug: nelarabine;   Other: pharmacological study
36 Unknown  Lung Screening Study
Condition: Lung Cancer
Interventions: Procedure: bronchoscopic and lung imaging studies;   Procedure: comparison of screening methods;   Procedure: computed tomography;   Procedure: radiography;   Procedure: study of high risk factors
37 Completed Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
Conditions: Liver Cancer;   Metastatic Cancer
Interventions: Drug: isolated perfusion;   Drug: melphalan
38 Terminated Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   de Novo Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: decitabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
39 Completed Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma
Interventions: Drug: temsirolimus;   Other: laboratory biomarker analysis
40 Active, not recruiting Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Adult Solid Neoplasm;   Lung Carcinoid Tumor;   Recurrent Gastrointestinal Neuroendocrine Tumor G1;   Recurrent Renal Cell Carcinoma;   Recurrent Uterine Corpus Sarcoma;   Stage III Renal Cell Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Uterine Sarcoma;   Stage IV Renal Cell Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Sarcoma
Interventions: Biological: Trebananib;   Drug: Temsirolimus;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years